Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
GME GameStop Corp
XELA Exela Technologies Inc
ARKK ARK Innovation ETF
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
BEPH Brookfield BRP Holdings (Canada) Inc
CHKP Check Point Software Technologies Ltd
FDX FedEx Corp
VLON Vallon Pharmaceuticals Inc
HCNEU Jaws Hurricane Acquisition Corp

Health Care : Biotechnology |
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Closing Price
Day's Change
-0.17 (-2.76%)
B/A Size
Day's High
Day's Low

10-day average volume:

Intel CEO Pat Gelsinger hopes to win back Apple by outcompeting it

8:08 pm ET October 17, 2021 (MarketWatch)

By Mike Murphy

'I've gotta make sure our products are better than theirs,' exec tells Axios

Intel Corp. Chief Executive Pat Gelsinger still hopes to win back Apple Inc. as a customer, but says Intel will have to outcompete the tech giant to do so.

In an interview aired Sunday night on "Axios on HBO," Gelsinger told Axios reporter Ina Fried that he doesn't blame Apple (AAPL) for dropping Intel (INTC) and deciding to make its own chips.

"Apple decided they could do a better chip themselves than we could," he said. "And, you know, they did a pretty good job. So what I have to do is create a better chip than they can do themselves. I would hope to win back this piece of their business, as well as many other pieces of business, over time."

"In the meantime, I've gotta make sure our products are better than theirs, that my ecosystem is more open -- and vibrant -- than theirs, and that we create a more compelling reason for developers and users to land on Intel-based products," Gelsinger said. "So I'm gonna fight hard to win [Apple CEO Tim Cook's] business in this area."

Intel had made chips for Apple's Macs since 2005, before Apple carried out a long-rumored switch last year to making its own custom chips.

Gelsinger noted that a reunion with Apple could take years, and mentioned that another option would be for Apple to eventually use Intel's chip-manufacturing facilities. Intel already makes chips for Inc. (AMZN) and Qualcomm Inc. (QCOM), among others.

Intel is scheduled to report quarterly earnings Thursday. Analysts expect nearly flat earnings and revenue compared with a year ago. Intel shares are up 9% year to date, compared to the S&P 500's 19% increase this year.

-Mike Murphy


(END) Dow Jones Newswires

October 17, 2021 20:08 ET (00:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.